Is PT-141 (Bremelanotide) Legal in Missouri?

What Is PT-141 (Bremelanotide) and Why Does Its Legal Status Matter?

PT-141 is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist, primarily at MC3R and MC4R in the central nervous system. Unlike sildenafil or tadalafil, which act peripherally on vascular smooth muscle, bremelanotide works centrally to increase sexual desire. The FDA approved the branded product Vyleesi in June 2019 based on two key Phase 3 trials (RECONNECT studies, combined N=1,247) showing a statistically significant increase in satisfying sexual events and a reduction in distress scores compared with placebo. 1

Legal status matters because "PT-141" circulates in multiple forms: the FDA-approved branded auto-injector, compounded versions prepared by 503A pharmacies, and unapproved research-chemical preparations sold online. Each form carries a different legal risk profile for both the prescriber and the patient in Missouri.

The Three Forms Circulating in Missouri

Vyleesi (branded, FDA-approved). Legally dispensed with a valid prescription at any licensed Missouri retail pharmacy.

503A compounded bremelanotide. Prepared by a state-licensed compounding pharmacy for an individual patient under a valid prescription. Legal under 21 U.S.C. § 353a when the active pharmaceutical ingredient (API) is sourced from an FDA-registered facility. 2

Unscheduled research chemicals sold without a prescription. Not legal for human use. The FDA has issued multiple warning letters to online peptide vendors since 2021 for selling injectable peptides without approved applications. 3

Federal Legal Framework for Bremelanotide

FDA Approval and NDA Status

The FDA granted New Drug Application (NDA) 210557 to AMAG Pharmaceuticals (now Cosette Pharmaceuticals) on June 21, 2019 for Vyleesi. 4 The labeled indication is acquired HSDD in premenopausal women. The product is a 1.75 mg/0.4 mL subcutaneous auto-injector administered at least 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than once per week. 5

Bremelanotide is not listed in any schedule of the Controlled Substances Act. Prescribers do not need a DEA CTP waiver or any special DEA registration beyond their standard DEA number. 6

503A Compounding Rules

Under the Drug Quality and Security Act (DQSA) of 2013, a licensed pharmacist or physician may compound bremelanotide for an individual patient provided:

• A valid patient-specific prescription exists before compounding begins.
• The API comes from an FDA-registered outsourcing facility or an FDA-inspected supplier.
• Bremelanotide is not on the FDA's 503A Bulks List, substances that are categorized as demonstrably difficult to compound or that appear on the withdrawn/removed list. As of the January 2025 update, bremelanotide does not appear on the FDA's "Category 1" or "Category 2" 503A bulk substances lists. 7
• The compounded preparation is not essentially a copy of a commercially available product (the "essentially a copy" provision requires the prescriber to note a clinical difference, such as a different concentration, route, or excipient).

503B Outsourcing Facilities

503B outsourcing facilities may compound bremelanotide without patient-specific prescriptions for office use, provided the drug is not a copy of an FDA-approved product and is not on the 503B Bulks List. Facilities must be registered with the FDA and comply with current good manufacturing practice (cGMP). 8

Missouri State Law and Bremelanotide

Missouri Controlled Substances Act

Missouri's Controlled Substances Act (Chapter 195, RSMo) mirrors the federal schedules but adds state-specific entries. Bremelanotide does not appear in Schedules I through V under Missouri law as of the 2024 revision. 9 A prescriber therefore does not need a Missouri-specific controlled substance registration to prescribe PT-141 in any form.

Missouri Board of Pharmacy Compounding Rules

The Missouri Board of Pharmacy enforces USP Chapter 795 (non-sterile) and USP Chapter 797 (sterile) standards for all licensed compounding pharmacies in the state. 10 Since bremelanotide is administered subcutaneously, any compounded preparation must meet USP 797 sterile standards, which include:

• Cleanroom ISO classification requirements (ISO 5 primary engineering control).
• Beyond-use dating based on sterility testing data or default conservative timelines.
• Ongoing environmental monitoring and pharmacist competency assessments. 11

Missouri-licensed pharmacies that ship compounded bremelanotide to Missouri patients from out-of-state must hold a Missouri non-resident pharmacy license. The receiving patient's prescription must be valid under Missouri law.

Missouri Medical Practice Act

Missouri Revised Statutes Chapter 334 governs physician licensing and the standard of care. 12 Off-label prescribing of bremelanotide (for example, in men with hypoactive sexual desire or in postmenopausal women) is legal in Missouri provided:

• A bona fide prescriber-patient relationship exists.
• The prescriber documents the clinical rationale.
• Informed consent discusses that the use is outside the FDA-approved indication.

The Missouri State Medical Association has not issued a position statement specifically restricting off-label peptide prescribing beyond the standard-of-care requirement. 13

Telehealth Prescribing in Missouri

Missouri enacted SB 681 in 2018, establishing a telehealth framework that allows prescribing after a telehealth encounter that meets standard-of-care requirements. 14 A clinician practicing via a Missouri-licensed telehealth platform may issue a valid bremelanotide prescription without an in-person visit, provided:

• The clinician holds a Missouri medical license.
• The clinical evaluation is sufficient to establish diagnosis.
• The prescription is transmitted to a licensed pharmacy.

Clinical Evidence Supporting Prescribing Decisions

RECONNECT Phase 3 Trials

The two RECONNECT studies (Study 301 and Study 302) enrolled a combined 1,247 premenopausal women with acquired, generalized HSDD. Participants received bremelanotide 1.75 mg subcutaneously or placebo on an as-needed basis over 24 weeks. 1

Key results from the pooled analysis:

• Mean increase in satisfying sexual events: 0.7 events per month above placebo (P<0.001).
• Female Sexual Function Index desire domain score increased by a mean of 0.3 points above placebo (P<0.001).
• Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score decreased by a mean of 0.3 points above placebo (P<0.001).
• Nausea was the most common adverse effect, occurring in 40% of the bremelanotide group vs. 1% in placebo. Transient increases in mean blood pressure (mean peak increase of approximately 2 mmHg systolic, 1 mmHg diastolic, resolving within 12 hours) were observed. 15

Mechanism of Action and MC4R Selectivity

Bremelanotide binds MC1R, MC3R, MC4R, and MC5R with varying affinity. MC4R activation in the medial preoptic area of the hypothalamus is the primary driver of increased sexual motivation in animal models. 16 A 2014 review in the Journal of Sexual Medicine summarized the central melanocortin pathway's role in both male and female sexual function, providing the biological basis for off-label use in men. 17

Bremelanotide vs. Flibanserin for HSDD

Flibanserin (Addyi, approved 2015) is the only other FDA-approved pharmacotherapy for HSDD in premenopausal women. Head-to-head trial data do not exist, but indirect comparisons from their respective key trials show bremelanotide is used on-demand while flibanserin requires daily dosing. A 2020 review in Obstetrics and Gynecology Clinics noted that patient preference between the two agents often depends on tolerability profile and dosing convenience. 18 Missouri prescribers may choose either agent based on individual patient factors.

How to Get a Legal PT-141 Prescription in Missouri

Step 1: Establish a Clinician-Patient Relationship

A valid prescription in Missouri requires a clinician-patient relationship. This may be established in person or via a qualifying telehealth encounter under Missouri SB 681. The clinician should perform or review relevant history, including hormonal status, medication review, and psychosocial contributors to low sexual desire.

Step 2: Obtain a Formal Diagnosis

HSDD (now reclassified as Female Sexual Interest/Arousal Disorder in DSM-5) requires distress caused by low desire, not merely low desire alone. 19 A clinician may use validated tools such as the FSDS-DAO or the Brief Profile of Female Sexual Function. Baseline testosterone and estradiol levels help rule out hormonal causes.

Step 3: Receive and Fill the Prescription

The prescriber transmits the Rx electronically to a licensed Missouri pharmacy. Options include:

• A retail pharmacy dispensing branded Vyleesi. Insurance coverage for Vyleesi is limited; AMAG's manufacturer coupon historically reduced out-of-pocket cost to approximately $99 per dose for eligible patients.
• A Missouri-licensed 503A compounding pharmacy, which may prepare a lower-cost version at a different concentration if the prescriber documents a clinical reason.
• An FDA-registered 503B outsourcing facility shipping to a Missouri-licensed prescriber for office use.

The HealthRX clinical team uses a three-gate framework when evaluating Missouri patients for compounded bremelanotide: (1) confirm HSDD diagnosis with a validated instrument, (2) verify no contraindications (cardiovascular disease, concurrent use of naltrexone or opioid agonists), and (3) confirm the compounding pharmacy holds a current Missouri pharmacy license or a Missouri non-resident pharmacy license before issuing any Rx.

Contraindications and Safety Flags

The FDA labeling for Vyleesi lists these contraindications: 5

• Known cardiovascular disease or high cardiovascular risk.
• Uncontrolled hypertension.
• Concomitant use with naltrexone (receptor competition) or any opioid agonist.

Missouri prescribers should note that the transient blood pressure increase observed in RECONNECT was self-limiting but may be clinically relevant in borderline-hypertensive patients. 15

Risks of Obtaining PT-141 Without a Prescription in Missouri

Purchasing injectable peptides from online research-chemical vendors and self-administering them carries significant risks beyond legal exposure:

Sterility. Research-chemical peptides are not manufactured under USP 797 or cGMP conditions. A 2021 CDC investigation linked compounded drug contamination to multiple patient fatalities, underscoring the importance of licensed compounding oversight. 20

Purity. Third-party testing of online peptide products has repeatedly identified incorrect peptide sequences, endotoxin contamination, and undisclosed excipients. 21

Legal. Purchasing a prescription drug without a valid prescription violates 21 U.S.C. § 353(b). Missouri statute § 195.020 also prohibits unlawful possession of certain substances, and while bremelanotide is not scheduled, importing unapproved drug products may violate 21 U.S.C. § 331. 22

Insurance, Cost, and Access in Missouri

Vyleesi carries a list price of approximately $800 to $1,000 per dose at major Missouri pharmacy chains. Commercial insurance coverage is inconsistent; a 2020 analysis found fewer than 30% of commercial formularies covered bremelanotide without prior authorization. 23 Missouri Medicaid (MO HealthNet) does not currently list Vyleesi on its preferred drug list as of 2024. 24

Compounded bremelanotide from a 503A pharmacy typically costs between $50 and $150 per vial (10 mg/mL, multi-dose), making it considerably more affordable. However, insurance does not reimburse compounded drugs, so the full cost is out-of-pocket.

Off-Label Use in Men: What Missouri Prescribers Should Know

Bremelanotide has been studied in men with erectile dysfunction and low sexual desire. A Phase 2 trial (N=221) published in the European Urology journal found subcutaneous bremelanotide produced an erection sufficient for intercourse in 80% of men who were non-responsive to sildenafil, with an effect onset within 30 to 60 minutes. 25

The drug is not FDA-approved for men. Off-label prescribing is legal in Missouri under Chapter 334, but prescribers must document:

• Review of the available evidence.
• Discussion of the unapproved status.
• Patient informed consent.

Many Missouri telehealth clinics do prescribe compounded bremelanotide off-label for men with psychogenic or mixed-etiology erectile dysfunction when PDE5 inhibitors are contraindicated or ineffective. 26

Summary of Missouri Legal Status at a Glance

| Category | Status in Missouri | |---|---| | Branded Vyleesi (Rx) | Legal with valid prescription | | Compounded 503A | Legal with valid Rx, licensed compounder, non-copy rule met | | Compounded 503B | Legal from registered outsourcing facility | | Research chemical (no Rx) | Not legal for human use | | DEA scheduling | Unscheduled federally and in Missouri | | Telehealth Rx | Legal under Missouri SB 681 framework | | Off-label (men, postmenopausal women) | Legal with documented clinical rationale |